Loading...
XSHG
603566
Market cap632mUSD
Dec 05, Last price  
13.08CNY
1D
0.46%
1Q
-9.48%
Jan 2017
-45.91%
IPO
6.34%
Name

Pulike Biological Engineering Inc

Chart & Performance

D1W1MN
XSHG:603566 chart
P/E
48.19
P/S
4.29
EPS
0.27
Div Yield, %
3.06%
Shrs. gr., 5y
1.35%
Rev. gr., 5y
9.47%
Revenues
1.04b
-16.77%
266,433,955292,354,213412,624,868417,525,649472,081,960475,689,703478,138,171583,102,019529,895,207608,059,265663,194,736928,511,8131,098,568,1031,228,016,4761,252,693,6031,042,561,095
Net income
93m
-46.82%
92,759,04283,990,635115,376,126129,212,279162,862,081140,256,921141,742,152188,002,145114,185,865135,614,826109,246,252227,744,103244,137,406167,820,374174,517,38892,806,499
CFO
269m
-4.95%
000147,960,866181,213,819151,206,579187,086,131253,026,482140,861,979126,271,903140,103,014261,831,612212,533,722233,129,092282,777,231268,788,363
Dividend
Jun 14, 20240.4 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Pulike Biological Engineering, Inc. engages in the research and development, production, and marketing of veterinary biological products and drugs. It offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. The company is headquartered in Luoyang, China.
IPO date
May 18, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT